Mitochondrial dysfunction and lipid homeostasis

Current Drug Metabolism

Volumn 13, Issue 10, 2012, Pages 1388-1400

  Vamecq, Joseph ^a,b,c   Dessein, Anne Frédérique ^b   Fontaine, Monique ^b   Briand, Gilbert ^b,d   Porchet, Nicole ^b   Latruffe, Norbert ^e,f   Andreolotti, Pierre ^e,f   Cherkaoui Malki, Mustapha ^e,f  

^a INSERM   (France)

^b Department of Biochemistry and Molecular Biology   (France)

^c UNIVERSITY OF MONS   (Belgium)

^d UNIV LILLE   (France)

^e boulevard Jeanne d'Arc   (France)

^f UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

ATP; Calcium; Ceramides; Fatty acids; Lipotoxicity; Metabolic syndrome; Mitochondria; Reactive oxygen species

Indexed keywords

ACETYL COENZYME A; ADENOSINE TRIPHOSPHATE; CALCIUM; CALCIUM ION; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID; FATTY ACID BINDING PROTEIN; FATTY ACID SYNTHASE; GLUTATHIONE REDUCTASE; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; LOW DENSITY LIPOPROTEIN RECEPTOR; MALONYL COENZYME A; NITRIC OXIDE SYNTHASE; NITRITE REDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; STEROIDOGENIC ACUTE REGULATORY PROTEIN; THIOREDOXIN REDUCTASE;

ADIPOCYTE; ADIPOGENESIS; ARTERY WALL; ATHEROSCLEROSIS; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CARCINOGENESIS; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM; ENERGY EXPENDITURE; ENZYME ACTIVITY; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FEEDING BEHAVIOR; GLUCOSE METABOLISM; HEART FUNCTION; HOMEOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; LIPOTOXICITY; LIVER METABOLISM; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENESIS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STEROL METABOLISM;

ADENOSINE TRIPHOSPHATE; CALCIUM; HOMEOSTASIS; HUMANS; LIPID METABOLISM; MITOCHONDRIA; MITOCHONDRIAL DISEASES; REACTIVE OXYGEN SPECIES;

EID: 84870427999     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012803762792     Document Type: Review

References (114)

1. Fritsche, L.; Weigert, C.; Häring, H.U.; Lehmann, R. How insulin receptor substrate proteins regulate the metabolic capacity of the liver-implications for health and disease. Curr. Med. Chem., 2008, 15, 1316-1329.
2. Palmieri, F. The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflugers Arch., 2004, 447, 689-709.
3. Murthy, M.S.; Pande, S.V. Malonyl-CoA binding site and the overt carnitine palmitoyltransferase activity reside on the opposite sides of the outer mitochondrial membrane. Proc. Natl. Acad. Sci. U.S.A., 1987, 84, 378-382.
4. Kashfi, K.; Cook, G.A. Topology of hepatic mitochondrial carnitine palmitoyltransferase I. Adv. Exp. Med. Biol., 1999, 466, 27-42.
5. Takeuchi, K.; Reue, K. Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis. Am. J. Physiol. Endocrinol. Metab., 2009, 296, E1195-209.
6. Rutledge A.C.; Su, Q.; Adeli, K. Apolipoprotein B100 biogenesis: a complex array of intracellular mechanisms regulating folding, stability, and lipoprotein assembly. Biochem. Cell Biol., 2010, 88, 251-267.
7. Sugden, M.C.; Holness, M.J.; Palmer, T.N. Fuel selection and carbon flux during the starved-to-fed transition. Biochem. J., 1989, 263, 313-323.
8. Turrens, J.F. Mitochondrial formation of reactive oxygen species. J. Physiol., 2003, 552, 335-344.
9. Omura, T. Mitochondrial P450s. Chem.Biol. Interact., 2006, 163, 86-93.
10. Sewer, M.B.; Li, D. Regulation of Steroid Hormone Biosynthesis by the Cytoskeleton. Lipids, 2008, 43, 1109-1115.
11. Miller, W.L. Steroidogenic acute regulatory protein (StAR), a novel mitochondrial cholesterol transporter. Biochim. Biophys. Acta, 2007, 1771, 663-676.
12. Miller, W.L. Mechanism of StAR's regulation of mitochondrial cholesterol import. Mol. Cell. Endocrinol., 2007, 265-266, 46-50.
13. Brand, M.D. The sites and topology of mitochondrial superoxide production. Exp. Gerontol., 2010, 45, 466-472.
14. Szabó, C.; Ischiropoulos, H.; Radi, R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov., 2007, 6, 662-680.
15. Chaudière, J.; Ferrari-Iliou, R. Intracellular antioxidants: from chemical to biochemical mechanisms. Food Chem. Toxicol., 1999, 37, 949-962.
16. Marí, M.; Morales, A.; Colell, A.; García-Ruiz, C.; Fernández-Checa, J.C. Mitochondrial glutathione, a key survival antioxidant. Antioxid. Redox Signal., 2009, 11, 2685-2700.
17. Imai, H.; Nakagawa, Y. Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free Radic. Biol. Med., 2003, 34, 145-169.
18. Zelko, I.N.; Mariani, T.J.; Folz, R.J. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic. Biol. Med., 2002, 33, 337-349.
19. Culotta, V.C.; Yang, M.; O'Halloran, T.V. Activation of superoxide dismutases: putting the metal to the pedal. Biochim. Biophys. Acta, 2006,1763, 747-758.
20. Liang, H.; Van Remmen, H.; Frohlich, V.; Lechleiter, J.; Richardson, A.; Ran, Q. Gpx4 protects mitochondrial ATP generation against oxidative damage. Biochem. Biophys. Res. Commun., 2007, 356, 893-898.
21. Rabilloud, T.; Heller, M.; Rigobello, M.P.; Bindoli, A.; Aebersold, R.; Lunardi, J. The mitochondrial antioxidant defence system and its response to oxidative stress. Proteomics, 2001, 1, 1105-1110.
22. Cox, A.G.; Winterbourn, C.C.; Hampton, M.B. Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signaling. Biochem. J., 2010, 425, 313-325.
23. Lacza, Z.; Snipes, J.A.; Zhang, J.; Horvath, E.M.; Figueroa J.P.; Szabó, C., Busija, D.W. Mitochondrial nitric oxide synthase is not eNOS, nNOS or iNOS. Free Rad. Biol. Med., 2003, 35, 1217-1228.
24. Ghafourifar, P.; Cadenas, E. Mitochondrial nitric oxide synthase. Trends Pharmacol. Sci., 2005, 26, 190-195.
25. Poyton, R.O.; Ball, K.A.; Castello, P.R. Mitochondrial generation of free radicals and hypoxic signaling. Trends Endocrinol. Metab., 2009, 20, 332-340.
26. Shiva, S.; Oh, J.Y.; Landar, A.L.; Ulasova, E.; Venkatraman, A.; Bailey, S.M.; Darley-Usmar, V.M. Nitroxia: The pathological consequence of dysfunction in the nitric oxide-cytochrome c oxidase signaling pathway. Free Rad. Biol. Med., 2005, 38, 297-306.
27. Rial, E.; Rodríguez-Sánchez, L.; Gallardo-Vara, E.; Zaragoza, P.; Moyano, E.; González-Barroso, M.M. Lipotoxicity, fatty acid uncoupling and mitochondrial carrier function. Biochim. Biophys. Acta, 2010, 1797, 800-806.
28. Schrauwen, P.; Schrauwen-Hinderling, V.; Hoeks, J.; Hesselink, M.K. Mitochondrial dysfunction and lipotoxicity. Biochim. Biophys. Acta, 2010, 1801, 266-271.
29. Atshavesa, B.P.; Martina, G.G.; Hostetlera, H.A.; McIntosha, A.L.; Kierb, A.B.; Schroeder, F. Liver fatty acid-binding protein and obesity. J. Nutr. Biochem., 2010, 21, 1015-1032.
30. Knudsen, J.; Neergaard, T.B.F.; Gaigg, B.; Jensen, M.V.; Hansen, J.K. Role of Acyl-CoA Binding Protein in Acyl-CoA Metabolism and Acyl-CoA-Mediated Cell Signaling. J. Nutr., 2000, 130, 294S-298S.
31. Rasmussen, J.T.; Rosendal, J., Knudsen, J. Interaction of acyl-CoA binding protein (ACBP) on processes for which acyl-CoA is a substrate, product or inhibitor. Biochem. J., 1993, 292, 907-913.
32. Schroeder, F.; Petrescu, A.D.; Huang, H.; Atshaves, B.P.; McIntosh, A.L.; Martin, G.G.; Hostetler, H.A.; Vespa, A.; Landrock, D.; Landrock, K.K.; Payne, H.R.; Kier, A.B. Role of Fatty Acid Binding Proteins and Long Chain Fatty Acids in Modulating Nuclear Receptors and Gene Transcription. Lipids, 2008, 43, 1-17.
33. Prentki, M.; Corkey, B.E. Are the beta-cell signaling molecule malonyl-CoA and cytosolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM. Diabetes, 1996, 45, 273-283.
34. Giorgi, C.; De Stefania,D.; Bononia, A.; Rizzutoc, R.; Pinton, P.Structural and functional link between the mitochondrial network and the endoplasmic reticulum. Int. J. Biochem. Cell Biol., 2009, 41, 1817-1827.
35. Hajnóczky, G.; Csordás, G.; Yi M. Old players in a new role: mitochondria-associated membranes, VDAC, and ryanodine receptors as contributors to calcium signal propagation from endoplasmic reticulum to the mitochondria. Cell Calcium, 2002, 32, 363-377.
36. Pizzo, P.; Pozzan, T. Mitochondria-endoplasmic reticulum choreography: structure and signaling dynamics. Trends Cell Biol., 2007, 17, 511-517.
37. Furt, F.; Moreau, P. Importance of lipid metabolism for intracellular and mitochondrial membrane fusion/fission processes. Int. J. Biochem. Cell Biol., 2009, 41, 1828-1836.
38. Sivitz, W.I.; Yorek, M.A. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid. Redox Signal., 2010, 12, 537-577.
39. Cnop, M.; Welsh, N.; Jonas, J.C.; Jörns, A.; Lenzen, S.; Eizirik, D.L. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes, 2005, 54 Suppl 2, S97-S107.
40. Vamecq, J.; Vallée, L.; Lesage, F.; Gressens, P.; Stables, J.P. Antiepileptic popular ketogenic diet: emerging twists in an ancient story. Prog. Neurobiol., 2005, 75, 1-28.
41. Azzu, V.; Jastroch, M.; Divakaruni, A.S.; Brand, M.D. The regulation and turnover of mitochondrial uncoupling proteins. Biochim Biophys Acta, 2010, 1797, 785-791.
42. Jastroch, M.; Divakaruni, A.S.; Mookerjee, S.; Treberg, J.R.; Brand, M.D. Mitochondrial proton and electron leaks. Essays Biochem., 2010, 47, 53-67.
43. Waldeck-Weiermair, M.; Duan, X.; Naghdi, S.; Khan, M.J.; Trenker, M.; Malli, R.; Graier, W.F. Uncoupling protein 3 adjusts mitochondrial Ca2+ uptake to high and low Ca2+ Signals. Cell Calcium, 2010, 48, 288-301.
44. Lowell, B.B.; Shulman, G.I. Mitochondrial dysfunction and type 2 diabetes. Science, 2005, 307(5708), 384-387.
45. de Ferranti, S.; Mozaffarian, D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin. Chem., 2008, 54, 945-955.
46. Guilherme, A.; Virbasius, J.V.; Puri, V.; Czech, M.P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell. Biol., 2008, 9, 367-377.
47. Petersen, K.F. Mitochondrial dysfunction in the elderly: possible role in insulin ressitance. Science, 2003, 300, 1140-1142.
48. De Pauw, A.; Tejerina, S.; Raes, M.; Keijer, J.; Arnould, T. Mitochondrial (dys)function in adipocyte (de)differentiation and systemic metabolic alterations. Am. J. Pathol., 2009, 175, 927-939.
49. Barbaro, G. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. Curr. Med. Chem., 2007, 14, 2734-2748.
50. Barbaro G., Iacobellis G. Metabolic syndrome associate with HIV and highly active retroviral therapy. Curr. Diab. Rep., 2009, 9, 37-42.
51. Maassen, J.A.; Romijn, J.A.; Heine, R.J. Fatty acid-induced mitochondrial uncoupling in adipocytes as a key protective factor against insulin resistance and beta cell dysfunction: do adipocytes consume sufficient amounts of oxygen to oxidise fatty acids? Diabetologia, 2008, 51, 907-908.
52. Carrière, A.; Carmona, M.C.; Fernandez, Y.; Rigoulet, M.; Wenger, R.H.; Pénicaud, L.; Casteilla, L. Mitochondrial reactive oxygen species control the transcription factor CHOP-10/GADD153 and adipocyte differentiation: a mechanism for hypoxia-dependent effect. J. Biol. Chem., 2004, 279, 40462-40469.
53. Gao, X.; Li, K.; Hui, X.; Kong, X.; Sweeney, G.; Wang, Y.; Xu, A.; Teng, M.; Liu, P.; Wu, D. Carnitine palmitoyltransferase-1A prevents free fatty acid induced adipocyte dysfunction through suppression of c-Jun N-terminal kinase. Biochem. J., 2011, 435, 723-732.
54. Chen, X.H.; Zhao, Y.P.; Xue, M.; Ji, C.B.; Gao, C.L.; Zhu, J.G.; Qin, D.N.; Kou, C.Z.; Qin, X.H.; Tong, M.L.; Guo, X.R. TNFalpha induces mitochondrial dysfunction in 3T3-L1 adipocytes. Mol. Cell Endocrinol., 2010, 328, 63-69.
55. Gnacińska, M.; Małgorzewicz, S.; Stojek, M.; Łysiak-Szydłowska, W.; Sworczak, K. Role of adipokines in complications related to obesity: a review. Adv. Med. Sci., 2009, 54, 150-157.
56. Stofkova, A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr. Regul., 2009, 43, 157-168.
57. Gustafson, B. Adipose tissue, inflammation and atherosclerosis. J. Atheroscler. Thromb., 2010, 17, 332-341.
58. Ziemke, F.; Mantzoros, C.S. Adiponectin in insulin resistance: lessons from translational research. Am. J. Clin. Nutr., 2010, 91, 258S-261S.
59. Purohit, V.; Gao, B.; Song, B.J. Molecular mechanisms of alcoholic fatty liver. Alcohol Clin. Exp. Res., 2009, 33, 191-205.
60. Pocai, A.; Lam, T.K.; Obici, S.; Gutierrez-Juarez, R.; Muse, E.D.; Arduini, A.; Rossetti, L. Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats. J. Clin. Invest., 2006, 116, 1081-1091.
61. Wolfgang, M.J., Lane, MD. The role of hypothalamic malonyl-CoA in energy homeostasis. J. Biol. Chem., 2006, 281, 37265-37269.
62. Wolfgang, M.J., Lane, M.D. Hypothalamic malonyl-coenzyme A and the control of energy balance. Mol. Endocrinol., 2008, 22, 2012-20.
63. Lane M.D.; Wolfgang, M.; Cha, S.H.; Dai, Y. Regulation of food intake and energy expenditure by hypothalamic malonyl-CoA. Int. J. Obes., 2008, 32 Suppl 4, S49-S54.
64. Wolfgang M.J.; Lane, M.D. Hypothalamic malonyl-CoA and CPT1c in the treatment of obesity. FEBS J., 2011, 278, 552-558.
65. Ono, H. The hypothalamus bridges the gap between physiology and biochemistry in high-fat diet-induced hepatic insulin resistance. Cell Cycle, 2009, 8, 2885-2887.
66. Brandon, M.; Baldi, P.; Wallace, D.C. Mitochondrial mutations in cancer. Oncogene, 2006, 25, 4647-4662.
67. Lu, J.; Sharma, L.K.; Bai, Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res., 2009, 19, 802-815.
68. Máximo, V.; Lima, J.; Soares, P.; Sobrinho-Simões, M. Mitochondria and cancer. Virchows Arch., 2009, 454, 481-495.
69. Ordys, B.B.; Launay, S.; Deighton, R.F., McCulloch, J.; Whittle, I.R. The role of mitochondria in glioma pathophysiology. Mol. Neurobiol., 2010, 42, 64-75.
70. Semenza, G.L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev., 2010, 20, 51-56.
71. Verschoor, M.L.; Wilson, L.A.; Singh, G. Mechanisms associated with mitochondrial-generated reactive oxygen species in cancer. Can. J. Physiol. Pharmacol., 2010, 88, 204-219.
72. Ishikawa, K.; Hayashi, J. A novel function of mtDNA: its involvement in metastasis. Ann. N. Y. Acad. Sci., 2010, 1201, 40-43.
73. Lin, H.; Lu, J.P.; Laflamme, P.; Qiao, S.; Shayegan, B.; Bryskin, I.; Monardo, L.; Wilson, B.C.; Singh, G.; Pinthus, J.H. Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies. Int. J. Oncol., 2010, 37, 761-766.
74. Linher-Melville, K.; Zantinge, S.; Sanli, T.; Gerstein, H.; Tsakiridis, T.; Singh, G. Establishing a relationship between prolactin and altered fatty acid β-oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. BMC Cancer, 2011, 11, 56.
75. Dakubo, G.D. Mitochondrial Genetics and Cancer. Chapter 2 The Warburg Phenomenon and Other Metabolic Alterations of Cancer Cells- DOI 10.1007/978-3-642-11416-8-2, Springer-Verlag Berlin Heidelberg 2010.
76. Modica-Napolitano, J.S.; Singh, K.K. Mitochondrial dysfunction in cancer. Mitochondrion, 2004, 4, 755-762.
77. Thupari, J.N.; Pinn, M.L.; Kuhajda, F.P. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem. Biophys. Res. Commun., 2001, 285, 217-223.
78. Baron, A.; Migita, T.; Tang, D.; Loda, M. Fatty acid synthase: a metabolic oncogene in prostate cancer? J. Cell. Biochem., 2004, 91, 47-53.
79. Flavin, R.; Zadra, G.; Loda, M. Metabolic alterations and targeted therapies in prostate cancer. J. Pathol., 2011, 223, 283-294.
80. Kuhajda, F.P. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition, 2000, 16, 202-208.
81. Kuhajda, F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res., 2006, 66, 5977-5980.
82. Grunt, T.W.; Wagner, R.; Grusch, M.; Berger, W.; Singer, C.F.; Marian, B.; Zielinski, C.C.; Lupu, R. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem. Biophys. Res. Commun., 2009, 385, 454-459.
83. Jin, Q.; Yuan, L.X.; Boulbes, D.; Baek, J.M.; Wang, Y.N.; Gomez-Cabello, D.; Hawke, D.H.; Yeung, S.C.; Lee, M.H.; Hortobagyi, G.N.; Hung, M.C.; Esteva, F.J. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res., 2010, 12, R96.
84. Kumar-Sinha, C.; Ignatoski, K.W.; Lippman, M.E.; Ethier, S.P.; Chinnaiyan, A.M. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res., 2003, 63, 132-139.
85. Menendez, J.A. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochim. Biophys. Acta, 2010, 1801, 381-391.
86. Menendez, J.A.; Vellon, L.; Mehmi, I.; Oza, B.P.; Ropero, S.; Colomer, R.; Lupu, R. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 10715-10720.
87. Vazquez-Martin, A.; Colomer, R.; Brunet, J.; Lupu, R.; Menendez, J.A. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif., 2008, 41, 59-85.
88. Vazquez-Martin, A.; Fernandez-Real, J.M.; Oliveras-Ferraros, C.; Navarrete, J.M.; Martin-Castillo, B.; Del Barco, S.; Brunet, J.; Menendez, J.A. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. Int. J. Oncol., 2009, 35, 1369-1376.
89. Kourtidis, A.; Srinivasaiah, R.; Carkner, R.D.; Brosnan, M.J.; Conklin, D.S. Peroxisome proliferator-activated receptor-gamma protects ERBB2-positive breast cancer cells from palmitate toxicity. Breast Cancer Res., 2009, 11, R16.
90. Kourtidis, A.; Jain, R.; Carkner, R.D.; Eifert, C.; Brosnan, M.J.; Conklin, D.S. An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. Cancer Res., 2010, 70, 1783-1792.
91. Vazquez-Martin, A.; Ortega-Delgado, F.J.; Fernandez-Real, J.M.; Menendez J.A. The tyrosine kinase receptor HER2 (erbB-2): from oncogenesis to adipogenesis. J. Cell. Biochem., 2008, 105, 1147-1152.
92. Duncan, J.G.; Finck, B.N. The PPARalpha-PGC-1alpha Axis Controls Cardiac Energy Metabolism in Healthy and Diseased Myocardium. PPAR Res., 2008, 2008, 253817.
93. Duncan, J.G. Peroxisome proliferator activated receptor-alpha (PPARα) and PPAR gamma coactivator-1alpha (PGC-1α) regulation of cardiac metabolism in diabetes. Pediatr. Cardiol., 2011, 32, 323-328.
94. Finck, B.N. The PPAR regulatory system in cardiac physiology and disease. Cardiovasc. Res., 2007, 73, 269-277.
95. Sugden, M.C.; Caton, P.W.; Holness, M.J. PPAR control: it's SIRTainly as easy as PGC. J. Endocrinol., 2010, 204, 93-104.
96. Ballinger, S.W. Mitochondrial dysfunction in cardiovascular disease. Free Radic. Biol. Med., 2005, 38, 1278-1295.
97. Chen, K., Thomas, S.R., Keaney, J.F. Jr. Beyond LDL oxidation: ROS in vascular signal transduction. Free Radic. Biol. Med., 2003, 35, 117-132.
98. Fearon, I.M.; Faux, S.P. Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J. Mol. Cell. Cardiol., 2009, 47, 372-381.
99. Galle, J.; Hansen-Hagge, T.; Wanner, C.; Seibold, S. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis, 2006, 185, 219-226.
100. Gutierrez, J.; Ballinger, S.W.; Darley-Usmar, V.M.; Landar, A. Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circ. Res., 2006, 99, 924-932.
101. Leopold, J.A.; Loscalzo, J. Oxidative risk for atherothrombotic cardiovascular disease. Free Radic. Biol. Med., 2009, 47, 1673-1706.
102. Rojas, A.; Figueroa, H.; Re, L.; Morales, M.A. Oxidative stress at the vascular wall. Mechanistic and pharmacological aspects. Arch. Med. Res., 2006, 37, 436-448.
103. Singh, U.; Jialal, I. Oxidative stress and atherosclerosis. Pathophysiology, 2006, 13, 129-142.
104. Boullier, A.; Bird, D.A.; Chang, M.K.; Dennis, E.A.; Friedman, P.; Gillotre-Taylor, K.; Hörkkö, S.; Palinski, W.; Quehenberger, O.; Shaw, P.; Steinberg, D.; Terpstra, V.; Witztum, J.L. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann. N. Y. Acad. Sci., 2001, 947, 214-222.
105. Brown, M.S.; Goldstein, J. L. Lipoprotein metabolism in the macrophage. Ann. Rev. Biochem., 1983, 52, 223-261.
106. Hofnagel, O.; Luechtenborg, B.; Weissen-Plenz, G.; Robenek, H. Statins and foam cell formation: impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochim. Biophys. Acta., 2007, 1771, 1117-1124.
107. Jialal, I.; Devaraj, S. The role of oxidized low density lipoprotein in atherogenesis. J. Nutr., 1996, 126, 1053S-1057S.
108. Yoshida, H.; Kisugi, R. Mechanisms of LDL oxidation. Clin. Chim. Acta, 2010, 411, 1875-1882.
109. Aronis, A.; Aharoni-Simon, M.; Madar, Z.; Tirosh, O. Triacylglycerol- induced impairment in mitochondrial biogenesis and function in J774.2 and mouse peritoneal macrophage foam cells. Arch. Biochem. Biophys., 2009, 492, 74-81.
110. Aronis, A.; Madar, Z.; Tirosh, O. Mechanism underlying oxidative stress-mediated lipotoxicity: exposure of J774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis. Free Radic. Biol. Med., 2005, 38, 1221-1230.
111. Aronis, A.; Madar, Z.; Tirosh, O. Lipotoxic effects of triacylglycerols in J774.2 macrophages. Nutrition, 2008, 24, 167-176.
112. Prieur, X.; Roszer, T.; Ricote, M. Lipotoxicity in macrophages: evidence from diseases associated with the metabolic syndrome. Biochim. Biophys. Acta, 2010, 1801, 327-337.
113. Houten, S.M.; Wanders R.J. A general introduction to the biochemistry of mitochondrial fatty acid α-oxidation. J. Inherit. Metab. Dis., 2010, 33, 469-477.
114. Schon, E.A.; Area-Gomez, E. Is Alzheimer's disease a disorder of mitochondria-associated membranes? J. Alzheimer Dis., 2010, 20 Suppl 2, S281-S292.